fSCIG 10% in pediatric primary immunodeficiency diseases: a European post-authorization safety study

Abstract Background The safety, tolerability, and immunogenicity of hyaluronidase-facilitated subcutaneous immunoglobulin (fSCIG) 10% (dual-vial unit of human immunoglobulin 10% and recombinant human hyaluronidase [rHuPH20]) were assessed in children with primary immunodeficiency diseases (PIDs). Me...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Peter Čižnár, Marion Roderick, Helen Schneiderova, Miloš Jeseňák, Gergely Kriván, Nicholas Brodszki, Stephen Jolles, Charles Atisso, Katharina Fielhauer, Shumyla Saeed-Khawaja, Barbara McCoy, Leman Yel
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	BMC 2024-09-01
Edice:	Allergy, Asthma & Clinical Immunology
Témata:	Hyaluronidase Immunoglobulins Inborn errors of immunity (IEI) Primary immunodeficiency diseases Patient safety Pediatrics
On-line přístup:	https://doi.org/10.1186/s13223-024-00904-9
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!